Mayo Clinic | Strategic Alliance Partners

October 26, 2023

While progress in outcomes has been greater in non–small cell lung cancer, recent advances, including molecularly targeted therapies against EGFR and ALK, checkpoint inhibitors that boost immune response, improved staging, and video-assisted surgery have all contributed to progress in treatment of all types of lung cancer, including in SCLC.

October 24, 2023

Panelists explore recent findings of the PATHFINDER study, focusing on the objectives, study design, key results, and differences from previous studies, shedding light on the potential of early cancer detection tests.

October 24, 2023

Shared insight into findings of the DETECT-A study, a prospective interventional trial, covering feasibility, safety, and performance of multicancer early detection tests in a healthcare system setting.

October 23, 2023

Ricardo D. Parrondo, MD, discusses the current treatment landscape of mantle cell lymphoma and highlights ongoing areas of investigation in other hematologic malignancies.

October 20, 2023

Lance C. Pagliaro, MD, discusses the efficacy of first-line avelumab maintenance therapy, as seen in the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

October 20, 2023

Muhamad Alhaj Moustafa, MD, MS, discusses the evolution of treatment options for patients with mantle cell lymphoma. 

October 19, 2023

Yi Lin, MD, PhD, discusses findings from the primary analysis of the phase 1/2 CARTITUDE-1 trial of the BCMA-targeting CAR T-cell therapy ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

October 18, 2023

Daniel S. Childs, MD, and colleagues spotlight future innovations in the management of metastatic hormone-sensitive prostate cancer, treatment sequencing for metastatic urothelial carcinoma, and key data with PARP inhibitor combinations in metastatic castration-resistant prostate cancer.

October 17, 2023

Muhamad Alhaj Moustafa, MD, MS, discusses the phase 3 SHINE trial, which evaluated ibrutinib given with bendamustine and rituximab in patients with mantle cell lymphoma.

October 17, 2023

Expert panelists delve into multicancer early detection testing and discuss its potential to revolutionize cancer screening, close healthcare gaps, and complement standard care approaches.

October 09, 2023

Oncology experts discuss the platinum chemotherapy shortage in the United States.

October 06, 2023

Muhamad Alhaj Moustafa, MD, MS, has improved the treatment of patients with mantle cell lymphoma, and the role that this agent has in the current treatment landscape.

October 06, 2023

Ricardo D. Parrondo, MD, discusses the clinical benefit seen with momelotinib in anemic myelofibrosis, and where it fits into the current treatment paradigm in this disease landscape.

October 03, 2023

Immunotherapy has become a valuable tool for the treatment of patients with various types of lymphomas because of its ability to specifically target cancer cells, particularly those in blood cancers.

September 29, 2023

Jeremy C. Jones, MD, discusses the applications of circulating tumor DNA testing in colorectal cancer.

September 29, 2023

Explore critical issues surrounding health disparities in cancer screening, as discussed by experts, and the urgent need to bridge gaps in access, trust, and follow-up care for underserved populations.

September 29, 2023

A panel of esteemed cancer experts explore the challenges and opportunities in cancer screening and identification, shedding light on the evolving landscape and its impact on clinical practice.

September 26, 2023

Stephen M. Ansell, MD, PhD, discusses the successes and challenges of utilizing immune therapy across the landscape of hematologic malignancies, the importance of increasing the understanding of how the immune system functions in patients with lymphoma, and ongoing research of immune therapy for this patient population.

September 25, 2023

Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.

September 25, 2023

The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.